# Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy

> **NCT00237146** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 38 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Zoledronic acid

## Key facts

- **NCT ID:** NCT00237146
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00237146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00237146, "Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00237146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*